PERCELLVAC-Sur

**PERCELLVAC-Sur** is an autologous dendritic cell (DC) vaccine therapy loaded with Survivin tumor-associated antigens (TAAs) for immunotherapy in glioblastoma (GBM). It involves ex vivo loading of patient-derived DCs with Survivin peptides, followed by intradermal and intravenous administration to elicit anti-tumor T-cell responses. Developed for newly diagnosed GBM post-resection, chemoradiotherapy (radiotherapy + temozolomide), and adjuvant temozolomide, it is administered in three doses on days 0, 14, and 28 (dose escalation: 1\u00d710^7, 2\u00d710^7, or 3\u00d710^7 DCs; 1 ml intradermal + 5 ml IV). The therapy targets Survivin-expressing GBM to enhance immunogenicity and survival, with ongoing evaluation of safety, tolerability, PFS, OS, and immune responses in phase I/II trials.[3][4]

Other names

PERCELLVACSurvivin-loaded dendritic cell injectionTargeted Survivin DC Cell Injection